Literature DB >> 10159

Studies on the kinetic effects of adenosine-3':5'-monophosphate-dependent phosphorylation of purified pig-liver pyruvate kinase type L.

O Ljunström, L Berglund, L Engström.   

Abstract

The effect of cyclic-AMP-dependent phosphorylation on the activity of isolated pig liver pyruvate kinase was studied. It was found that the major kinetic effect of the phosphorylation was to reduce the affinity for the substrate phosphoenolpyruvate, K0.5 for this substrate increasing from 0.3 to 0.9 mM upon phosphorylation. The cooperative effect with phosphoenolpyruvate was enhanced, the Hill constant nH increasing concomitantly from 1.1 to 1.5. V was unaltered. The change in activity occurred in parallel with the phosphate incorporation, except during the initial part of the reaction, when inactivation was correspondingly slower. The affinity for the second substrate ADP was unchanged, with an apparent Km of 0.3 mM at saturating concentration of phosphoenolpyruvate. Likewise, the requirement for potassium was unaffected, whereas the phosphoenzyme required a higher concentration of magnesium ions for maximal activity, compared with the control enzyme. The inhibitory effect of the phosphorylation was counteracted by positive effectors, fructose 1,6-biphosphate in micromolar concentrations completely activated the phosphoenzyme, resulting in an enzyme with properties similar to the fructose 1,6-biphosphate-activated unphosphorylated enzyme, with K0.5 for phosphoenolpyruvate about 0.025 mM and with a Hill constant of 1.1. Hydrogen ions were also effective in activating the phosphoenzyme. Thus, when pH was lowered from 8 to 6.5 the inhibition due to phosphorylation was abolished. The phosphoenzyme was sensitive to further inhibition by negative effectors such as ATP and alanine. 2 mM ATP increased K0.5 for phosphoenolpyruvate to 1.5 mM and nH to 2.3. The corresponding values with alanine were 1.3 mM and 1.9. Phosphorylation is thought to be an additional mechanism of inhibition of the enzyme under gluconeogenetic conditions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10159     DOI: 10.1111/j.1432-1033.1976.tb10837.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  A study of regulation of gluconeogenesis and the supply of cytosolic reducing equivalents for lactate formation in rat kidney-cortical-tubule fragments incubated with pyruvate.

Authors:  E D Saggerson
Journal:  Biochem J       Date:  1978-07-15       Impact factor: 3.857

2.  Are all regions of folded proteins that undergo ligand-dependent order-disorder transitions targets for allosteric peptide mimetics?

Authors:  Aron W Fenton
Journal:  Biopolymers       Date:  2013-11       Impact factor: 2.505

3.  Effect of glucagon on metabolite compartmentation in isolated rat liver cells during gluconeogenesis from lactate.

Authors:  E A Siess; D G Brocks; H K Lattke; O H Wieland
Journal:  Biochem J       Date:  1977-08-15       Impact factor: 3.857

4.  Pancreatic islets contain the M2 isoenzyme of pyruvate kinase. Its phosphorylation has no effect on enzyme activity.

Authors:  M J MacDonald; C M Chang
Journal:  Mol Cell Biochem       Date:  1985-10       Impact factor: 3.396

5.  An activating interaction between the unphosphorylated n-terminus of human liver pyruvate kinase and the main body of the protein is interrupted by phosphorylation.

Authors:  Aron W Fenton; Qingling Tang
Journal:  Biochemistry       Date:  2009-05-12       Impact factor: 3.162

6.  In vivo regulation of glycolytic and gluconeogenic enzyme gene expression in newborn rat liver.

Authors:  S Lyonnet; C Coupé; J Girard; A Kahn; A Munnich
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

7.  Mutational mimics of allosteric effectors: a genome editing design to validate allosteric drug targets.

Authors:  Qingling Tang; Maria T Villar; Antonio Artigues; John P Thyfault; Udayan Apte; Hao Zhu; Kenneth R Peterson; Aron W Fenton
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.